2024
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
Kerekes D, Frey A, Prsic E, Tran T, Clune J, Sznol M, Kluger H, Forman H, Becher R, Olino K, Khan S. Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. JAMA Oncology 2024, 10: 342-351. PMID: 38175659, PMCID: PMC10767643, DOI: 10.1001/jamaoncol.2023.6025.Peer-Reviewed Original ResearchNon-small cell lung cancerEnd of lifeMonth of deathImmunotherapy initiationCohort studyMAIN OUTCOMEStage IV non-small cell lung cancerCharlson-Deyo comorbidity indexHigh metastatic burdenInitiation of immunotherapyNational prescribing patternsRisk-adjusted patientsImmune checkpoint inhibitorsRetrospective cohort studyStage IV melanomaPercentage of patientsHigh-volume centersLocation of metastasesLow-volume centersOdds of deathCell lung cancerNational Clinical DatabaseLow-volume facilitiesDrug Administration approvalCheckpoint inhibitors
2021
Comparative efficacy of docetaxel versus novel hormonal agent in de novo metastatic hormone-sensitive prostate cancer: Real-world data curated by deidentified chart abstraction.
Liaw B, Guin S, Jun T, Ayers K, Patel B, O'Connell T, Dietz M, Klein M, Prentice T, Newman S, Fink M, Zhou X, Schadt E, Chen R, Oh W. Comparative efficacy of docetaxel versus novel hormonal agent in de novo metastatic hormone-sensitive prostate cancer: Real-world data curated by deidentified chart abstraction. Journal Of Clinical Oncology 2021, 39: e17047-e17047. DOI: 10.1200/jco.2021.39.15_suppl.e17047.Peer-Reviewed Original ResearchNovel hormonal agentsFailure-free survivalLonger failure-free survivalClinical variablesHormonal agentsComparative efficacyDe novo metastatic hormone-sensitive prostate cancerMetastatic hormone-sensitive prostate cancerMultivariable Cox proportional hazards modelsHormone-sensitive prostate cancerImproved failure-free survivalSuperior failure-free survivalWorse failure-free survivalMount Sinai Health SystemCox proportional hazards modelHigh metastatic burdenPost-treatment PSALow-volume diseaseSinai Health SystemKaplan-Meier methodAddition of docetaxelStandard of careMultivariable model analysisImportant clinical questionsProportional hazards model
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply